Key result
Single-pill amlodipine/atorvastatin enabled 62.9% (JEWEL 1) and 50.6% (JEWEL 2) of patients to achieve both country-specific blood pressure and LDL-C targets at 16 weeks.
Why the study?
Does single-pill amlodipine/atorvastatin improve the attainment of country-specific blood pressure and LDL-C targets in patients with uncontrolled blood pressure?
Does single-pill amlodipine/atorvastatin improve the attainment of country-specific blood pressure and LDL-C targets in patients with uncontrolled blood pressure?
Single-pill amlodipine/atorvastatin effectively helps over half of patients achieve both blood pressure and LDL-C targets in a real-world setting.
Answers are grounded in this paper and cite their sources.
May support dual-target control with single-pill therapy in hypertension; extends real-world data but leaves open need for RCTs.
BACKGROUND: Single-pill amlodipine/atorvastatin targets the two most common modifiable cardiovascular risk factors, hypertension and dyslipidaemia. We evaluated the clinical utility of this single pill to help patients across Europe and Canada achieve country-specific targets for blood pressure (BP) and low-density lipoprotein cholesterol (LDL-C). DESIGN: Two 16-week, open-label studies conducted in 122 study centres across the United Kingdom and Canada (JEWEL 1) and 113 centres across 11 European countries (JEWEL 2). METHODS: Patients with uncontrolled BP and controlled/uncontrolled LDL-C qualifying for treatment according to local governing guidelines were administered single-pill amlodipine/atorvastatin with appropriate lifestyle modification. Eight dosages of amlodipine/atorvastatin (5/10-10/80 mg) were titrated to achieve country-specific BP and LDL-C targets. The primary outcome was the percentage of patients reaching country-specific BP and LDL-C targets in 16 weeks. RESULTS: Among 2245 patients enrolled in the studies (JEWEL 1, n = 1138; JEWEL 2, n = 1107), 62.9% in JEWEL 1 and 50.6% in JEWEL 2 achieved both country-specific BP and LDL-C goals. BP was reduced by 20.4/10.7 and 21.8/12.6 mmHg in JEWEL 1 and JEWEL 2, respectively, and reductions in LDL-C were 0.90 mmol/l (34.8 mg/dl) and 1.09 mmol/l (42.2 mg/dl), respectively. The most common adverse events were peripheral oedema (11.0%), joint swelling (2.9%) and headache (2.9%), of which, only oedema was linked to study treatment. CONCLUSION: Single-pill amlodipine/atorvastatin is an effective and well-tolerated treatment, which in a real-world setting helped more than half of the patients achieve both BP and LDL-C targets as recommended by local guidelines. Although fewer patients met their goals in JEWEL 2 than JEWEL 1, reductions in BP and LDL-C were slightly greater in JEWEL 2, suggesting that the observed differences are likely because of more stringent targets in Europe than in the UK/Canada.
No takes yet. Share an insight, caveat, or question.
Gensini et al. (2009) studied Hypertension and dyslipidaemia (n=2,245). Single-pill amlodipine/atorvastatin was evaluated on Percentage of patients reaching country-specific BP and LDL-C targets in 16 weeks. Single-pill amlodipine/atorvastatin enabled 62.9% (JEWEL 1) and 50.6% (JEWEL 2) of patients to achieve both country-specific blood pressure and LDL-C targets at 16 weeks.
Synapse has enriched 10 related papers. Consider them for comparative context: